Collection: RETATRUTIDE

Retatrutide is a synthetic peptide classified as a triple receptor agonist, engineered to simultaneously target the GLP-1, GIP, and glucagon receptors. This combined mechanism of action has made it one of the most actively studied compounds in contemporary metabolic and endocrinology research. Within the published literature, retatrutide has been investigated in models of energy balance, glucose regulation, lipid metabolism, and hepatic function, where its multi-receptor profile is of particular interest to researchers comparing single- and dual-agonist compounds.

Every batch of retatrutide supplied by Ontario Peptide undergoes our three-stage verification process: source-facility HPLC analysis, independent community and third-party auditing, and our own final clearance including exclusive endotoxin testing. The result is a research compound whose identity, purity, mass, and endotoxin levels are confirmed against a published Certificate of Analysis before it is cleared for dispatch — so the material in your vial matches the data on paper.

We supply retatrutide in 10 mg and 30 mg presentations to suit both initial study design and extended, multi-phase research. Automatic volume discounts apply across the catalog, and all orders ship discreetly Canada-wide from within Ontario, with no customs or border delays.

All products are intended exclusively for in-vitro research and laboratory use. Not for human or animal consumption, diagnosis, or treatment.